During the first phase of the MIPR, we not only worked to develop fundamental technologies, but also contributed to innovations in drug discovery, diagnostics, and therapeutic biomarkers.
"From April 2010, the``Strategic Research Program for Molecular Imaging""ill be initiated by MEXT to link the research achievements made thus far to clinical applications and experimental research."